GT Biopharma Inc is a biotechnology company focused on developing innovative immuno-oncology therapies to treat various forms of cancer. The company specializes in harnessing the power of the immune system to identify and destroy cancer cells through its proprietary platforms, which include novel antibody constructs and immune cell engineering. By advancing its therapeutic candidates through clinical trials, GT Biopharma aims to improve treatment outcomes for patients suffering from solid tumors and hematological malignancies. Through strategic partnerships and cutting-edge research, the company is dedicated to addressing unmet medical needs in the oncology space. Read More
ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Biotech Resurgence: Platforms and Pipelines of Today's Innovators investor conference, held April 16, 2026, are now available.
ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual investor conference, Biotech Resurgence: Platforms and Pipelines of Today's Innovators, taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. ET.
NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's own defenses, developing therapies that empower natural killer (NK) cells to seek and destroy malignant cells. These next-generation approaches combine precision, potency, and the potential for fewer side effects than conventional treatments.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
